ONCLive CLL eNews
Combination Trials Signal Next Wave of Treatment for CLL
Within the last decade, the FDA has approved 8 new agents for the treatment of patients with chronic lymphocytic leukemia.
Novel Agents and Approaches Continue to Advance Through CLL Pipeline
Mazyar Shadman, MD, MPH, discusses the evolution of therapy in chronic lymphocytic leukemia and how physicians are working to balance novel agents with additional modalities.
CLL Landscape Continues to Expand With Addition of Venetoclax
Javier A. Pinilla-Ibarz, MD, PhD, discusses updates in the treatment of patients with chronic lymphocytic leukemia.
CLL: The Rapidly Evolving Treatment Landscape
Susan M. O’Brien, MD, shares insight into the quickly evolving treatment landscape, including the current evaluations of BTK inhibitors such as acalabrutinib and zanubrutinib, as well as the potential future of the PI3K inhibitor duvelisib, for patients with relapsed or refractory chronic lymphocytic leukemia.
Evaluating Pharmacologic Agents in Relapsed/Refractory CLL
Michael Choi, MD, elucidates essential indications and considerations for treating relapsed/refractory chronic lymphocytic leukemia with approved pharmacologic agents.